#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Colorectal cancer Dementia Alzheimer's type Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Anal cancer Immune-mediated enterocolitis Hyperadrenocorticism Pulmonary hypertension Breast cancer Wolfram syndrome Gastrointestinal neuroendocrine tumour Neuroendocrine cell hyperplasia of infancy Iron overload Burkitt's lymphoma refractory Cold type haemolytic anaemia Brain abscess Hereditary hypophosphataemic rickets CDKL5 deficiency disorder Gaucher's disease type I More trials…

    Learn about Rare Diseases

    Bronchopulmonary dysplasia – Basic Information Mantle cell lymphoma stage IV – Treatment Undifferentiated sarcoma – Basic Information Marginal zone lymphoma – Diagnostics Kearns-Sayre syndrome X-linked lymphoproliferative syndrome – Life with Disease Mantle cell lymphoma refractory – Basic Information Mucopolysaccharidosis I Idiopathic inflammatory myopathy – Diagnostics Optic glioma – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Autologous Pancreatic Islets Fludarabine Fianlimab Bi 1015550 Fluorouracil Rp-1664 Sulfate Adg126 Selinexor Tiaprofenic Acid GOLD SODIUM THIOSULFATE Siltuximab Exagamglogene Autotemcel Morphine Hydrochloride Napabucasin Filgotinib ZINC GLUCONATE Specific Nucleic Acid Sna-Her1 Sasanlimab Sitravatinib Malate Flupentixol Decanoate More therapies…

    Learn about Your Condition

    Hepatoblastoma Pancreatic failure Thymic carcinoma Skin neoplasm excision Fallopian tube cancer Foot deformity Arthritis infective Hypercholesterolaemia Strongyloidiasis Sarcoma Immune system disorder High-grade B-cell lymphoma Skin wrinkling Diminished ovarian reserve Alcohol use disorder More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Plasma cell myeloma

  • Cevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cevostamab
    • Carfilzomib
    • Daratumumab
    Czechia Denmark France Germany Greece Italy +2

  • Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Dexamethasone Acetate
    • Teclistamab
    • Bortezomib
    Germany

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Daratumumab
    • Dexamethasone
    • Lenalidomide
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma
    Investigated Drugs:
    • Carfilzomib
    • Daratumumab
    • Dexamethasone
    Norway

  • A Study of Linvoseltamab in Adult Patients with High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Hypergammaglobulinaemia benign monoclonal
    • Plasma cell myeloma
    Investigated Drugs:
    • Diphenhydramine Hydrochloride
    • Linvoseltamab
    • Dexamethasone
    Belgium France Ireland Italy Poland Spain

  • Study of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Talquetamab
    • Teclistamab
    • Daratumumab
    Italy The Netherlands Norway Spain
1 2 3 … 27
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!